|
Simcere Pharmaceutical Group Ltd is a pharmaceutical company focused on the research, development, and commercialization of drugs. Its portfolio spans oncology, neurology, autoimmune diseases, cardiovascular conditions, and anti-infection therapies. Key marketed products include Endostar, ENWEIDA, ENZESHU, COSELA, Sanbexin, Xianlinda, and Leruiping. The company maintains an active pipeline with compounds such as SIM0500, SIM0508, SIM0505, SIM0686, SIM0609, Suvemcitug, and Zemprocitinib in various stages of clinical trials. Simcere operates in China and the United States, with several drugs holding Investigational New Drug approvals in both regions. The company collaborates with partners such as Roche for the global development of the tri-specific antibody SIM0660. Its products are included in national medical insurance catalogs and clinical practice guidelines. Summarised from the company's own disclosures, fiscal year ended Apr 2026 |
Industry Drug Manufacturers - General | Homepage simcere.com |
| Sector Healthcare | IR page — | |
|
Tags
oncology, neurology, autoimmune diseases, cardiovascular, anti-infection, antibody-drug conjugates, bispecific antibodies, small molecule inhibitors, clinical trials, innovative drugs, Endostar, ENWEIDA, ENZESHU, COSELA, Sanbexin, Xianlinda, Leruiping, QUVIVIQ, Suvemcitug, Zemprocitinib, Deulorlatinib, SIM0500, SIM0508, SIM0505, SIM0686, SIM0609, SIM0692, SIM0811, SIM0610, SIM0278, SIM0532, SIM0660, Jiangsu Simcere Medical Diagnostics Co. Ltd.
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | HK$ 26.88B |
| Market cap (USD) | $ 3.426B |
| P/E | 17.21 |
| PEG | 1.33 |
| P/BV | 2.41 |
| P/S | 2.62 |
| P/OCF | 8.30 |
| P/FCF | 19.84 |
| Dividend yield | 2.0% |
| Turnover / mcap | 0.12% |
| Returns | |
|---|---|
| ROE | 16.3% |
| ROI | 12.8% |
| ROIC | 14.9% |
| Profit margin | 17.4% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | 12.9% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | 11.1% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | 33.3% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpAnnouncements and reports published on HKEXnews, newest first, monthly and next-day returns, proxy forms and board-meeting notices included. The link opens the announcement on HKEXnews. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Simcere Pharmaceutical Group Ltd
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AVEE | 0.13% | 127,000 | $ 170.28K | Nov 16, 2026 |
| AVES | 0.07% | 804,000 | $ 1.078M | Nov 16, 2026 |
| AVEM | 0.04% | 7,252,000 | $ 9.723M | Nov 16, 2026 |
| DFSE | 0.03% | 119,000 | $ 165.197K | Nov 12, 2026 |
| DFEM | 0.01% | 916,000 | $ 1.272M | Nov 12, 2026 |
| DFAE | 0.01% | 803,000 | $ 1.115M | Nov 12, 2026 |
| DFAX | 0.01% | 604,000 | $ 838.477K | Nov 12, 2026 |

















苏公网安备 32010202010345号
